AACR 2023: Treatment with immunotherapy alone produces ‘exceptional’ response rates in some melanoma patients
Data from a national clinical trial shows that a striking 89% of patients with desmoplastic…
Browsing: Featured Events
ANZGOG 2023 ASM Review by Dr Michelle Wilson
Written by Dr Michelle Wilson, Medical Oncologist & ANZGOG New Zealand Director Introduction The Australia…
EAU 2023: Delaying treatment for localised prostate cancer does not increase mortality risk
Active monitoring of prostate cancer has the same high survival rates after 15 years as…
SABCS 2022: Breast-conserving therapy may be a treatment option for some patients with multiple breast lesions
Patients with multiple tumours in the same breast who underwent a lumpectomy followed by radiation…
To Infinity and Beyond…a Wrap Up of the Biggest RANZCR Annual Scientific Meeting to Date
Last month saw a record turnout for the 72nd RANZCR Annual Scientific Meeting (ASM) in…
ESMO 2022: Cell therapy improves PFS in advanced melanoma, first phase 3 study shows
A novel treatment strategy with personalised cell therapy significantly improves progression-free survival compared to standard…
WCLC 2022: Sub-lobar surgery for peripheral non-small cell lung cancer non-inferior to lobectomy
A large international study of patients with non-small cell lung cancer tumours that are two…
RANZCR Hosts New Zealand Annual Scientific Meeting 2022
The Royal Australian and New Zealand College of Radiologists (RANZCR) today opens its New Zealand…
ASCO 2022: Nimotuzumab significantly improves overall survival for K-Ras wild-type advanced pancreatic cancer
The addition of nimotuzumab to gemcitabine (Gemzar) increases overall survival in patients with K-Ras wild-type advanced pancreatic…
ASCO 2022: ctDNA may help identify the need for adjuvant therapy in stage II colon cancer
In patients with stage II colon cancer where cancer DNA was not present in the…